Compare Clorox Co (CLX) vs Freeport-McMoRan Inc (FCX) Price & Performance

Clorox (CLX) trades at $106.54, down 1.58% on the day, with a bullish technical signal from moving averages but neutral oscillators. Recent Q4 2026 earnings beat estimates with EPS of $1.66 versus $1.64 expected, though revenue declined year-over-year. The company faces margin pressure from inflation but forecasts fiscal 2027 sales growth of 13-14%, supported by the GOJO acquisition and easing ERP disruptions. Cash flow from operations improved to $981 million in 2025, but net cash flow was negative $37 million.

Outlook is mixed: valuation ratios like P/E of 21.99 are reasonable, but high P/B of 142.11 signals premium pricing. Analyst consensus is cautious with 69% hold ratings and a $97.50 price target below current levels. Key risks include persistent cost inflation, competitive pressure from private labels, and volatile earnings. The dividend increase to $1.25 per share provides income support, but investors should weigh recovery prospects against macroeconomic headwinds.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.